Tenet Healthcare (THC) Dips More Than Broader Market: What You Should Know

In the latest trading session, Tenet Healthcare (THC) closed at $202.00, marking a -3% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.34%. On the other hand, the Dow registered a loss of 0.94%, and the technology-centric Nasdaq increased by 0.16%. Heading into today, shares of the hospital operator had gained 3.09% over the past month, outpacing the Medical sector's gain of 0.82% and the S&P 500's gain of 1.19%.The investment community will be paying close attention to the earnings performance of Tenet Healthcare in its upcoming release. In that report, analysts expect Tenet Healthcare to post earnings of $4.05 per share. This would mark year-over-year growth of 17.73%. Our most recent consensus estimate is calling for quarterly revenue of $5.45 billion, up 7.44% from the year-ago period. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $16.15 per share and a revenue of $21.27 billion, indicating changes of +35.94% and 0%, respectively, from the former year. It's also important for investors to be aware of any recent modifications to analyst estimates for Tenet Healthcare. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Tenet Healthcare presently features a Zacks Rank of #3 (Hold). Valuation is also important, so investors should note that Tenet Healthcare has a Forward P/E ratio of 12.53 right now. For comparison, its industry has an average Forward P/E of 9.46, which means Tenet Healthcare is trading at a premium to the group. It is also worth noting that THC currently has a PEG ratio of 0.88. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The average PEG ratio for the Medical - Hospital industry stood at 0.88 at the close of the market yesterday. The Medical - Hospital industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 199, positioning it in the bottom 19% of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. #1 Semiconductor Stock to Buy (Not NVDA)The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tenet Healthcare Corporation (THC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks